MX2020003472A - Variante e isoforma de anticuerpos con actividad biologica reducida. - Google Patents

Variante e isoforma de anticuerpos con actividad biologica reducida.

Info

Publication number
MX2020003472A
MX2020003472A MX2020003472A MX2020003472A MX2020003472A MX 2020003472 A MX2020003472 A MX 2020003472A MX 2020003472 A MX2020003472 A MX 2020003472A MX 2020003472 A MX2020003472 A MX 2020003472A MX 2020003472 A MX2020003472 A MX 2020003472A
Authority
MX
Mexico
Prior art keywords
isoforms
isoform
biological activity
antibody
antibody variant
Prior art date
Application number
MX2020003472A
Other languages
English (en)
Inventor
Nobuyuki Tanaka
Kensaku Hosoguchi
Maki Kuwayama
Chifumi Seida
Yosuke Watanabe
Satoshi Saitoh
Masakazu Fukuda
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2020003472A publication Critical patent/MX2020003472A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a Variantes e isoformas de anticuerpos que tienen una actividad mimética de FVIII reducida en comparación con el Emicizumab, en donde las variantes de los anticuerpos tienen algunos residuos de aminoácido específicos en la región variable escindidos y faltantes (Variantes con corte de Q-CDR), y las isoformas de anticuerpo tienen uniones de disulfuro entre las cadenas pesadas que son menos susceptibles a la reducción bajo condiciones reductoras suaves (Isoformas de Disulfuros Protegidos).
MX2020003472A 2017-11-01 2018-10-31 Variante e isoforma de anticuerpos con actividad biologica reducida. MX2020003472A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017212179 2017-11-01
PCT/JP2018/040436 WO2019088143A1 (ja) 2017-11-01 2018-10-31 生物活性が低下した抗体バリアントおよびアイソフォーム

Publications (1)

Publication Number Publication Date
MX2020003472A true MX2020003472A (es) 2020-08-03

Family

ID=66331990

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003472A MX2020003472A (es) 2017-11-01 2018-10-31 Variante e isoforma de anticuerpos con actividad biologica reducida.

Country Status (19)

Country Link
US (1) US20200283544A1 (es)
EP (1) EP3705496A4 (es)
JP (2) JPWO2019088143A1 (es)
KR (1) KR20200074209A (es)
CN (1) CN111479829A (es)
AR (1) AR113816A1 (es)
AU (1) AU2018361430A1 (es)
BR (1) BR112020008393A2 (es)
CA (1) CA3079053A1 (es)
CL (1) CL2020001113A1 (es)
CR (1) CR20200229A (es)
IL (1) IL274265A (es)
MA (1) MA50534A (es)
MX (1) MX2020003472A (es)
PE (1) PE20210553A1 (es)
SA (1) SA520411871B1 (es)
SG (1) SG11202003833TA (es)
TW (1) TW201930352A (es)
WO (1) WO2019088143A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
CN109661241A (zh) 2016-09-06 2019-04-19 中外制药株式会社 使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法
SG11202003833TA (en) 2017-11-01 2020-05-28 Chugai Pharmaceutical Co Ltd Antibody variant and isoform with lowered biological activity
TW202340249A (zh) * 2021-12-22 2023-10-16 日商中外製藥股份有限公司 生物活性降低之抗體變體
CN114544839A (zh) * 2022-01-20 2022-05-27 未名生物医药有限公司 一种抗人神经生长因子抗体的电荷变异体检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2006109592A1 (ja) 2005-04-08 2006-10-19 Chugai Seiyaku Kabushiki Kaisha 血液凝固第viii因子の機能代替抗体
CN101460622A (zh) * 2006-03-31 2009-06-17 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
US9670269B2 (en) * 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
BRPI0716762A2 (pt) * 2006-09-13 2013-09-24 Abbott Lab melhorias da cultura celular
EP3689912A1 (en) * 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
MX355060B (es) * 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
WO2012091023A1 (ja) * 2010-12-27 2012-07-05 協和発酵キリン株式会社 培地およびキレート剤を含む水溶液の調製方法
EP2788097A4 (en) 2011-12-07 2015-09-09 Amgen Inc IGG2 DISULFIDE ISOFORMATION SEPARATION
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
WO2016164708A1 (en) * 2015-04-10 2016-10-13 Adimab, Llc Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
US20200270363A1 (en) * 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
SG11202003833TA (en) 2017-11-01 2020-05-28 Chugai Pharmaceutical Co Ltd Antibody variant and isoform with lowered biological activity

Also Published As

Publication number Publication date
AU2018361430A1 (en) 2020-06-11
TW201930352A (zh) 2019-08-01
WO2019088143A1 (ja) 2019-05-09
BR112020008393A2 (pt) 2020-11-03
RU2020117440A3 (es) 2022-04-01
CA3079053A1 (en) 2019-05-09
KR20200074209A (ko) 2020-06-24
EP3705496A1 (en) 2020-09-09
MA50534A (fr) 2020-09-09
SA520411871B1 (ar) 2023-12-19
AR113816A1 (es) 2020-06-17
CL2020001113A1 (es) 2020-11-20
SG11202003833TA (en) 2020-05-28
CR20200229A (es) 2020-07-12
EP3705496A4 (en) 2021-12-08
CN111479829A (zh) 2020-07-31
PE20210553A1 (es) 2021-03-17
JPWO2019088143A1 (ja) 2020-11-12
IL274265A (en) 2020-06-30
RU2020117440A (ru) 2021-12-01
JP2024037761A (ja) 2024-03-19
US20200283544A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
MX2020003472A (es) Variante e isoforma de anticuerpos con actividad biologica reducida.
MX2021009800A (es) Pares de cadena pesada-cadena ligera de inmunoglobulina modificados geneticamente y usos de estos.
TN2017000020A1 (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
CL2020001262A1 (es) Plataforma de presentación en endosporas basadas en paenibacillus, productos y métodos relacionados.
ECSP13013097A (es) Coagonistas del receptor de glucagón/glp-1
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
BR112022007677A2 (pt) L-asparaginase recombinante
EA201591454A1 (ru) Связывающие внеклеточный матрикс синтетические пептидогликаны
BR112018011516A2 (pt) corrente de serra abrasiva
CO2017005624A2 (es) Composiciones oftálmicas estabilizadas de omega 3
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
MX2021000142A (es) Composiciones y metodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas.
AR114062A1 (es) Barras trilladoras del cóncavo de cosechadora
AR095527A1 (es) Formulaciones de polipéptido fc-factor ix
MY165953A (en) Methods and compositions for treating inflammation and ischemic injury
MX2016007960A (es) Composiciones y metodos para reducir los alegernos de gato en el medio ambiente.
AR092691A1 (es) Composicion farmaceutica que comprende rebamipida
BR112017019251A2 (pt) dispositivo de fotopletismografia do tipo reflectância
BR112015019183A2 (pt) longarina para veículo ferroviário, estrutura inferior de veículo ferroviário e veículo ferroviário
ES2514140B1 (es) Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento
MX2015012905A (es) Formulaciones de factor viii recombinantes.
UA118653C2 (uk) Суперагоністи глікопротеїнового гормону тривалої дії
BR112014026766A2 (pt) pano de limpeza aprimorado
AR095730A1 (es) Comprimido con contenido de fructosa
BR112016009962A2 (pt) superagonistas de ação prolongada de hormônio glicoproteico